An Open label Clinical Study to evaluate the safety and gastrointestinal tolerance(Product Compliance) of MaxvidaTM Advance in Hospitalized patients requiring isocaloric formulafor enteral tube feeding

Modi Mundi Pharma Private Limited0 个研究点目标入组 15 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Ready to Sign informed consent form or informed consent form signed by legally acceptable representatives.
•2. Aged 18 years and above.
•3. Gender: Male & Female.
•4. Hospitalized patients requiring isocaloric formula for enteral feeding.
•5. Can tolerate enteral tube feeding.
•6. Estimated duration of Hospital stay equal to or greater than 2 days.

•1. Receiving tube feeding prior to hospitalization.
•2. Patients less than 18 years of age.
•3. Patients having allergy to constituents of MaxvidaTM Advance.
•4. Any evidence of organ dysfunction or any clinically significant deviation
•from the normal, in physical or clinical determinations.
•5. History of renal, hepatic, cardiovascular, respiratory, skin, hematological,
•endocrine, neurological or gastrointestinal diseases.

发起方

Modi Mundi Pharma Private Limited